Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc.
1:14-cv-00935
Overview
Parties
Defendant
Mylan Pharmaceuticals Inc. Operating Company
Represented By
0 Attorneys ListedPlaintiff
Alkermes Pharma Ireland Limited NPE (University / Research)
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.
Coalition For Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.
Coalition For Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.
Coalition For Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.
Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.
Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc.
Acorda Therapeutics Inc. v. Par Pharmaceutical Inc.
Acorda Therapeutics Inc. v. Sun Pharmaceutical Industries Limited
Acorda Therapeutics Inc. v. Apotex Corp.
Acorda Therapeutics Inc. v. Accord Healthcare Inc.
Acorda Therapeutics Inc. v. Alkem Laboratories Ltd.
Patents Involved
There are 5 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5540938
Formulations and their use in the treatment of neurological diseases
|
Filed: 1994-10-24
Issued: 1996-07-30
|
Expired (Term Ended)
+1375d PTA
Expires: 2018-07-30
|
|
|
US8007826
Sustained release aminopyridine composition
|
Filed: 2004-12-13
Issued: 2011-08-30
|
Active (0.5 yrs remaining)
+894d PTA
Expires: 2027-05-26
|
|
|
US8354437
Method of using sustained release aminopyridine compositions
|
Filed: 2005-04-08
Issued: 2013-01-15
|
Active (1.4 yrs remaining)
+1119d PTA
Expires: 2028-05-01
|
|
|
US8440703
Methods of using sustained release aminopyridine compositions
|
Filed: 2011-11-18
Issued: 2013-05-14
|
Active (5.0 yrs remaining)
Expires: 2031-11-18
|
|
|
US8663685
Sustained release aminopyridine composition
|
Filed: 2011-07-20
Issued: 2014-03-04
|
Expired (Term Ended)
Expires: 2025-02-26
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
High PTA (+1375 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).